Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VIVSBullishCorporate Developmentsnews

High materiality8/10

VivoSim Regains Nasdaq Compliance and Outlines 500%+ FY2027 Revenue Growth

Aug 6, 2026, 8:10 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regaining Nasdaq compliance reduces listing risk and improves liquidity; cash runway is boosted by Lilly milestone and new financing; strong FY2027 growth guidance supports revenue visibility, potentially lifting multiple valuation metrics despite recent equity dilution from warrants.

AI summary

What happened, with direct paths to the underlying reporting

VivoSim regained Nasdaq compliance following July events, including a $5.0 million milestone from Eli Lilly and a $1.0 million escrow release. It also closed a July financing that raised $4.0 million gross ($3.6 million net), boosting cash to about $10.1 million. The company reiterates 500%+ FY2027 revenue growth guidance driven by NAM-based contract research services.

Nasdaq staff indicated VivoSim regained compliance with Rule 5550(b)(1). This improves liquidity.
Lilly paid a $5M milestone; $1M released from escrow. FXR sale tie-in noted.
July 17 financing: gross $4M; net $3.6M; warrants issued. Warrants issued.
Cash on hand ~$10.1M as of Aug 3, 2026. Liquidity strong.
Shares outstanding rose to 13.39M by Aug 3; warrants added about 9.9M shares.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.